Evidence map›Paper›PMID 42326004›Full record

ArticleFrontiers in cell and developmental biology2026

Integrating multi-omics and reverse network toxicology to identify pollutant risks and potential intervention targets in pulmonary arterial hypertension.

Shuying You, Yinhui Sun, Na Li, Hong Xie, Xiangbo Zeng, Xianli Su, Dan Liu, Chun Shao, Aiguo Dai

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuying YouDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital), Changsha, Hunan, China.
Yinhui SunHunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha, Hunan, China.
Na LiDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital), Changsha, Hunan, China.
Hong XieDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital), Changsha, Hunan, China.
Xiangbo ZengDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital), Changsha, Hunan, China.
Xianli SuHunan Provincial Key Laboratory of Vascular Biology and Translational Medicine, Changsha, Hunan, China.
Dan LiuCollege of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese medicine, Changsha, China.
Chun ShaoDepartment of Respiratory and Critical Care Medicine, The Second People's Hospital of Hunan Province (Hunan Provincial Brain Hospital), Changsha, Hunan, China.
Aiguo DaiCollege of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese medicine, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Idiopathic pulmonary arterial hypertension (PAH) is a progressive cardiovascular disorder with high mortality. Although both genetic and environmental factors are implicated in its pathogenesis, the underlying mechanisms remain unclear. Methods: We integrated transcriptomic data from PAH lung tissue, GWAS summary statistics, and QTL data for DNA methylation, gene expression, and plasma protein. Core dysregulated genes were first identified via differential expression and protein-protein interaction network analysis. Using summary-data-based Mendelian randomization (SMR), we systematically evaluated potential potential genetic associations between methylation, expression, or protein levels of candidate genes and PAH risk, with the HEIDI test to distinguish causality from pleiotropy. Key findings were validated by examining gene expression trends in two independent cohorts. Finally, reverse network toxicology was applied: environmental pollutants targeting identified genes were screened using the CTD, their binding potential assessed via molecular docking, and effects of a candidate pollutant on gene expression and cell proliferation validated Results: We identified 254 differentially expressed genes in PAH. Among these, TAGLN2 exhibited a significant positive association with PAH risk at three molecular levels-DNA methylation, gene expression, and plasma protein, suggesting a pathogenic role. Specifically, increased TAGLN2 protein abundance (HR = 9.00, 95% CI: 1.52-53.16) and gene expression levels (HR = 9.00, 95% CI: 1.52-53.16) were associated with higher PAH risk, while its methylation sites (e.g., cg13892570, cg16107628) showed a negative association. Validation in two independent cohorts confirmed that TAGLN2 expression was upregulated in the lung tissue of PAH patients. Reverse toxicology predicted eight environmental pollutants as potential TAGLN2-targeting agents, including PFOS, dibutyl phthalate, bisphenols, and benzo[a]pyrene. Molecular docking indicated that all these compounds could bind stably to the TAGLN2 protein (binding free energy < -5.0 kcal/mol), with PFOS exhibiting the strongest binding affinity (-8.9 kcal/mol). Conclusion: This study prioritizes TAGLN2 as a genetically associated candidate gene for PAH and identifies environmental pollutants that may target TAGLN2. While the

Indexed as

environmental pollution riskidiopathic pulmonary arterial hypertensionmulti-omicsreverse network toxicologySMR analysis

Identifiers

PMID42326004
PMCPMC13279435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.